As expected, trametinib fully inhibited the phosphorylation of ERK (p < 0.05) but, surprisingly, also increased the level of AKT phosphorylation (p < 0.05, Figure 4) as observed in the meningioma cell lines (Figure 1). The gene discussed is AKT1; the disease is meningioma.